Mario B. Guanti
Modena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: March 17, 2026
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective Study.
Journal: Antibodies (Basel, Switzerland)
Published: July 24, 2025
Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study.
Journal: Clinical and experimental dermatology
Published: July 01, 2025
Letter: Effectiveness and Safety of Tralokinumab for the Elderly with Atopic Dermatitis in a Real-World Setting-IL AD.
Journal: Dermatitis : contact, atopic, occupational, drug
Published: June 05, 2025
JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).
Journal: Dermatology and therapy
Published: May 22, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.
Journal: International journal of dermatology
Published: May 21, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.
Journal: Journal of clinical medicine
Published: February 05, 2025
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study.
Journal: American journal of clinical dermatology
Published: January 29, 2025
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: December 05, 2024
Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study.
Journal: Clinical and experimental dermatology
Published: October 11, 2024
Short-term effectiveness and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis: results from a 16-week real-world multicenter retrospective study - il AD (Italian landscape atopic dermatitis).
Journal: The Journal of dermatological treatment
Published: October 10, 2024
Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study.
Journal: Clinical and experimental dermatology
Published: September 23, 2024
Last Updated: 09/26/2026